Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice

Combination of radiation therapy, bempegaldesleukin, and checkpoint blockade eradicates advanced solid tumors and metastases in mice

Background Current clinical trials are using radiation therapy (RT) to enhance an antitumor response elicited by high-dose interleukin (IL)-2 therapy or immune checkpoint blockade (ICB). Bempegaldesleukin (BEMPEG) is an investigational CD122-preferential IL-2 pathway agonist with prolonged in vivo h...

Full description

Bibliographic Details
Main Authors: Willem W Overwijk, Zachary S Morris, Paul M Sondel, Deborah H Charych, Amy K Erbe, Jacquelyn A Hank, Alexander L Rakhmilevich, Won Jong Jin, Peter M Carlson, Alexander A Pieper, Ravi B Patel, Daniel V Spiegelman, Jen Birstler
Format: Article
Language:English
Published: BMJ Publishing Group 2021-06-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/9/6/e002715.full

Internet

https://jitc.bmj.com/content/9/6/e002715.full

Similar Items